ArticleDiabetes & metabolism journal2021

Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway.

Ji-Yeon Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.